A MedTech go-to-market strategy is the deliberate plan for turning a freshly certified device into paid hospital revenue. The CE mark is the starting line, not the finish. The plan answers seven questions: which channel reaches the buyer, which hospital becomes the first reference site, how the device is priced against a real budget line, how long the sales cycle actually runs, which key opinion leaders validate the clinical claim, what proof points move the deal, and which mistakes kill the first twelve months. Founders who treat GTM as the second act of the regulatory project — started before certification, not after — land first revenue in months. Founders who wait for the certificate before thinking about selling lose a full year discovering a market they could have built in parallel.

By Felix Lenhard and Tibor Zechmeister. Last updated 10 April 2026.

TL;DR

  • The CE mark is the start of the MedTech go-to-market strategy, not the end. Everything downstream of the certificate is harder and slower than founders expect.
  • Channel choice — direct sales, distributors under Article 14 of the MDR, or a hybrid — is the single biggest GTM decision and should be made before certification, not after.
  • The first hospital is a reference sale, not a revenue sale. Pick it for defensibility, not price.
  • Pricing is set by the budget line the hospital already has, not by the cost of goods plus a margin. Start from the buyer's ledger.
  • MedTech sales cycles run nine to eighteen months for a new device in a new hospital. Plan runway accordingly.
  • Key opinion leader development starts two years before launch, not two months. Clinical champions from the investigation phase become the first public voices.
  • Every claim used in sales material is bound by MDR Article 7 — no claim beyond the intended purpose, no implied benefit that is not supported by the evidence. GTM and regulatory share the same sentence.

CE mark is the starting line, not the finish

Founders spend two years raising money, running clinical investigations, fighting with the Notified Body, and polishing the technical file. The certificate arrives. The team opens a bottle. The next morning everyone goes back to their desks and nobody knows who sells the first unit or how.

This is the most predictable failure mode in MedTech. The entire company has been pointed at the regulatory finish line for so long that the go-to-market question has been treated as a problem for "after certification." After certification, the runway is shortest, the team is tired, the investors are impatient, and the sales cycle is about to reveal that it takes nine to eighteen months to close a first hospital. Companies that discover their GTM plan in that window rarely survive it.

The correct frame is that the CE mark is a prerequisite, not an achievement. A device without a CE mark cannot be sold in the EU. A device with a CE mark and no GTM plan cannot be sold either. The certificate unlocks a door. It does not walk through it. Treat GTM as a parallel project that runs alongside the regulatory project from the moment the intended purpose is stable. By the time the certificate lands, the first reference site, the first distributor conversation, the first pricing model, and the first clinical champion should already be in place. The certificate is the last missing ingredient, not the first.

Distribution channel choice: direct, distributor, hybrid

The first structural GTM decision is how the device reaches the buyer. There are three options and the differences are not stylistic.

Direct sales. The company hires its own sales force and sells directly to hospitals. Margins are highest. Customer relationships are owned. Feedback loops are fastest. The cost is a real sales team — typically one or two senior people per country, plus clinical support — and a long build-up before the first euro arrives. Direct makes sense when the device has a high per-unit price, a concentrated buyer population, and a founder who can personally close the first deals.

Distributors. The company partners with an existing distributor who already sells into the target hospitals. Under MDR Article 14, distributors have specific legal obligations — verifying that the device bears the CE marking, that the EU declaration of conformity exists, that labelling and instructions for use are in place, and that the importer and manufacturer are identifiable on the device. (Regulation (EU) 2017/745, Article 14.) A serious distributor will ask for all of this before signing. A distributor who does not ask is a warning sign, not a shortcut. Distributor deals give you reach without a sales team, at the cost of 25 to 45 percent of the end price, less customer intimacy, and a slower feedback loop on product issues.

Hybrid. Direct in one or two home-country markets where the founder can run the sales motion personally, distributors in the rest of Europe where hiring is unrealistic. This is the model most capital-efficient MedTech startups settle on after the first twelve months. It combines a learning loop in the home market with scalable coverage abroad.

The decision should be made before certification because the regulatory file, the quality agreements, the labelling, and the vendor paperwork all differ depending on the channel. A distributor onboarding against an unfinished QMS is a slow, painful process. A distributor onboarding against a clean Article 14 pack is routine.

The first hospital: a reference sale, not a revenue sale

The first hospital to buy your device is the most important customer you will ever have. Not because of the money — the money is almost always small — but because every subsequent buyer will ask the same two questions. "Who else uses this?" and "Where can we see it in a real setting?" The first site answers both.

Choose the first site for defensibility, not for price. The ideal profile is a hospital whose name is recognised in your target segment, whose lead clinician is willing to be publicly associated with the device, whose patient population matches your intended purpose exactly, and whose workflow is close enough to the average that other sites can relate to it. A niche reference site at a prestigious centre is worth more than three average sites that nobody has heard of.

The cheapest way to get a first site is to convert a clinical investigation site into a commercial customer. The hospitals that ran your clinical investigation already know the device, already have trained staff, and already have a workflow around it. Moving them from investigation to routine use is mostly a paperwork change — a commercial agreement, a supply contract, and the switch from investigational to CE-marked device. Founders who delay clinical partner conversations until after certification forfeit this bridge and end up cold-starting their first site from scratch.

Do not expect the first site to pay full price. Expect to discount heavily, give extended payment terms, or deliver bundled training and support for free. The first site is a reference asset. You are paying for the reference with the discount. The second and third sites are easier because you now have a reference. By site number five, the discount disappears.

Pricing: start from the buyer's budget line, not from cost-plus

First-time MedTech founders price their device with a cost-plus calculation. Add up the bill of materials, the allocated fixed cost, the target gross margin, and print the number. Then they walk into a hospital and discover the number has nothing to do with any budget line the hospital actually holds.

The correct starting point is the other direction. Find the existing budget line your device competes with or replaces. This might be a reimbursement code, a disposable category the hospital buys by the box, a capital equipment line, or a procedure cost the hospital already tracks. Work out what the hospital currently spends per case, per procedure, per patient, or per year on the thing your device changes. That number is the ceiling. Your price has to sit below it by enough margin that the buyer has a clear economic story to tell internally.

Then work backwards. If the hospital currently spends 400 euros per case on the alternative and your device can defensibly replace it for 250 euros per case, you have 150 euros of buyer savings to split. You do not capture all of it — capturing all of it leaves the buyer with no reason to switch. A reasonable split gives the buyer enough savings to justify the switching cost and leaves you enough margin to fund the sales motion. Only after that exercise do you check whether the resulting price covers your cost of goods and your allocated fixed cost. If it does not, you have a cost problem or a product-market fit problem, and no amount of pricing cleverness will fix it.

Pricing conversations with the first three or four hospitals will teach you more about the real ceiling than any desk research. Treat early pricing as a learning process. Lock it down once you have data from real deals, not before.

Sales cycle reality: nine to eighteen months is the default

A first-time MedTech founder arrives expecting the sales cycle of consumer software. A click-through funnel. A webinar. A two-week trial. A monthly subscription. None of this exists in the hospital sale.

The realistic sales cycle for a new MedTech device into a new hospital is nine to eighteen months from first contact to purchase order. The cycle runs through a predictable sequence. First contact with a clinical champion. Champion validates the device in their own setting. Champion introduces the device to their head of department. Department raises the topic with procurement. Procurement requests QMS documentation, ISO 13485 evidence, vendor qualification paperwork, and a quality agreement. A value analysis committee — in the larger hospitals — reviews the proposal on its monthly cadence. The budget holder signs off once the economic story is clear and the procurement file is clean. Finance issues the purchase order. Logistics handles delivery and first use.

Each of those steps can take weeks. Several of them can stall for months if the champion goes on leave, the budget cycle resets, or procurement raises a paperwork question nobody expected. Planning runway on a six-month sales cycle is how companies run out of money three months before the first purchase order lands.

The consequence for GTM planning is that the first conversations have to start before the CE mark, not after. A founder who begins outreach nine months before certification lands the first deal roughly at the moment of certification. A founder who begins outreach the week after certification lands the first deal a year later.

Key opinion leader development: start two years early

Key opinion leaders are the senior clinicians whose opinion moves other clinicians. A KOL endorsement does not close a deal on its own, but the absence of one makes most deals impossible. Hospitals do not adopt new devices on the word of the sales rep. They adopt on the word of a peer their own clinicians trust.

KOL development is slow because trust is slow. A clinician who has never heard of your company will not publicly endorse your device no matter how good it is. A clinician who has watched the device mature across the clinical investigation phase, who has been consulted on the intended purpose, who has seen the evidence build, and who has met the founder several times over eighteen months will consider endorsing it — if the device is good and the endorsement is earned.

The practical rule is to begin KOL conversations at the same time as the clinical investigation planning, roughly two years before the intended CE mark. The KOL pipeline and the clinical investigation site pipeline overlap substantially — the same senior clinicians who become investigation principal investigators are often the same clinicians who become post-launch public voices. Treat the clinical investigation as a KOL development programme that also produces clinical evidence. Both outputs matter.

KOL relationships are bound by MDR Article 7 on claims. Any public statement a KOL makes about the device that the company supports, promotes, or distributes has to stay inside the intended purpose and the evidence base. A KOL who claims more than the evidence supports exposes the company to an Article 7 violation on promotional materials. (Regulation (EU) 2017/745, Article 7.) The discipline is to brief KOLs on what can and cannot be said, and to never push them toward claims that exceed the file.

Proof points that actually move the deal

A MedTech sale is closed on a small number of proof points, not on feature lists. Feature lists are what founders write and what nobody reads. Proof points are what buyers cite when they argue for the device internally.

Four kinds of proof points carry weight.

Clinical evidence. The results of the clinical investigation or the published literature that underpins the clinical evaluation. A peer-reviewed paper with the device's name on it is worth more than any marketing collateral.

Economic evidence. A worked example of the budget impact at a reference site. "At site X the device reduced the per-case cost from 400 euros to 260 euros across 1,200 cases in the first year." Specific, sourced, and defensible.

Reference sites. Named hospitals, named departments, named clinicians who will take a phone call from a prospective buyer. One strong reference is worth ten testimonials.

Regulatory cleanliness. A complete Article 14 pack for distributors, a QMS certificate, a risk management file that survives procurement's technical review. These are table stakes but their absence is a deal-killer.

The sales team — whether that is the founder, a distributor, or a hired rep — should walk into every meeting with these four categories prepared. Anything beyond them is noise.

Common MedTech GTM mistakes

  • Treating the CE mark as the end of the project. The certificate unlocks selling. It does not do any selling. Start GTM before certification or pay for the delay in lost runway.
  • Choosing the channel after certification. Direct versus distributor changes the QMS, the labelling, the vendor paperwork, and the quality agreements. Decide early or redo everything.
  • Pricing cost-plus. The hospital does not care what the device costs to build. They care what budget line it fits into. Start from the ledger.
  • Planning on a six-month sales cycle. The realistic cycle is nine to eighteen months. Build the cash-flow model against the realistic number or run out of money.
  • Waiting to build KOL relationships until after launch. KOLs take two years to cultivate. The clinical investigation phase is when the relationships are built.
  • Running one pitch for every role in the decision-making unit. Champion, budget holder, and procurement speak different languages. Run four variants of the same pitch.
  • Making claims that exceed the intended purpose. Article 7 of the MDR forbids misleading claims in promotional material. Sales enthusiasm that drifts beyond the file is a compliance incident, not a growth hack.

The Subtract to Ship angle on GTM

Every GTM activity should trace back to either a specific MDR requirement or a named line in the business model. If it cannot be traced to either, it is drag.

Applied to MedTech go-to-market strategy, Subtract to Ship produces a short list.

  • Every sales conversation in phase one should be with a named person in a named role at a named hospital. Generic "market interest" is not a GTM activity.
  • Every piece of sales collateral should map to one proof point category — clinical, economic, reference, or regulatory. Slides that do not map to one of those four get cut.
  • Every claim in every deck has to sit inside the intended purpose and the evidence base. Article 7 is the test. (Regulation (EU) 2017/745, Article 7.)
  • Every distributor relationship has to be supported by a clean Article 14 pack. Distributors without the pack are not partners, they are future compliance incidents. (Regulation (EU) 2017/745, Article 14.)
  • Every pricing model should begin with the buyer's budget line, not the cost of goods. Pricing that cannot be traced to a real ledger is wishful.
  • Every KOL relationship should be a clinical investigation relationship first. Double-use the time and money.

Read the Subtract to Ship framework for MDR for the same discipline across the whole certification project.

Reality Check — Where do you stand on GTM?

Answer these honestly. If more than two are weak, your go-to-market plan is not ready for the week after certification.

  1. Have you decided whether you will sell direct, through distributors, or hybrid, and does the regulatory file match that decision?
  2. Do you have a named first reference site, with a named clinical champion, and a clear plan to convert them from clinical investigation site to commercial customer?
  3. Can you state your price as a function of the buyer's existing budget line, with a real number from a real buyer conversation?
  4. Does your cash-flow model assume a nine-to-eighteen-month sales cycle for the first three hospitals, or is it built on a six-month assumption?
  5. Have you started KOL development at least eighteen months before your target CE mark date?
  6. Can you produce, on request, a complete Article 14 pack for any distributor conversation — CE marking evidence, declaration of conformity, labelling, and instructions for use?
  7. Do your sales materials contain only claims that sit inside the intended purpose and the clinical evaluation?
  8. If the CE mark landed tomorrow, do you know the exact first three meetings you would take and who would take them?

Frequently Asked Questions

When should a MedTech startup start working on go-to-market strategy? The moment the intended purpose is stable — typically during the clinical investigation phase, eighteen to twenty-four months before the target CE mark date. The sales cycle for a first hospital runs nine to eighteen months, KOL relationships take two years to build, and channel choice affects the regulatory file. Starting GTM after the certificate lands is the single most common reason good devices fail commercially in their first year.

Direct sales or distributors for a first MedTech launch? Hybrid is the default for capital-efficient startups. Direct in one or two home-country markets where the founder can close the first deals personally and learn the sales motion. Distributors in the rest of Europe where building a local team is unrealistic. The direct market funds the learning and the distributor markets fund the reach.

How long does the MedTech sales cycle actually take? Nine to eighteen months is the realistic range for a new device in a new hospital. The cycle runs through clinical champion validation, department-level approval, procurement review, value analysis committee assessment in larger hospitals, budget sign-off, and finally the purchase order. Each step can stall for weeks or months, and planning runway on a shorter cycle is how MedTech companies run out of money just before their first deal closes.

How do you price a medical device for a first launch? Start from the hospital's existing budget line — the reimbursement code, the disposable category, the capital line, or the per-case cost your device competes with. Work out the buyer's current spend, estimate the realistic savings your device offers, and split the savings so the buyer has a clear economic story and you retain enough margin to fund the sales motion. Only then check that the price covers your cost of goods. Cost-plus pricing from the other direction almost always produces a number hospitals will not pay.

What is a key opinion leader in MedTech and when do you start building the relationship? A key opinion leader is a senior clinician whose professional opinion moves other clinicians. KOL endorsement does not close deals by itself but the absence of one makes most deals impossible. Relationship-building starts roughly two years before the target launch, typically during the clinical investigation phase, because the same senior clinicians who run investigation sites become the post-launch public voices. Any public statement a KOL makes about the device has to stay inside the intended purpose and the evidence base to avoid an Article 7 claim violation.

What does MDR Article 14 mean for distributor relationships? Article 14 of the MDR sets specific obligations on distributors — verifying that the device bears the CE marking, that the EU declaration of conformity has been drawn up, that labelling and instructions for use are in place, and that the importer and manufacturer are identifiable on the device. A serious distributor will ask the manufacturer for all of this before signing an agreement. The manufacturer's job is to maintain a clean pack that meets those requirements so the distributor onboarding is routine rather than a months-long paperwork struggle.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, consolidated text. Articles cited: Article 7 (claims); Article 14 (general obligations of distributors). Official Journal L 117, 5.5.2017.
  2. Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices. Official Journal L 80, 20.3.2023.

This post is part of the MedTech Startup Strategy and PMF series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. The CE mark is the starting line of the go-to-market strategy, not the finish. Build the plan in parallel with the regulatory project, or pay for the delay in lost runway after the certificate lands.